CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 11 enrolled
Drug / intervention
Nutropin AQdrug
Likely dose
Nutropin AQ 0.0125 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00444964
NCT00444964Phase 3Completed
CompareCT.gov

Growth Hormone Use in Adults With Prader-Willi Syndrome

Children's Mercy Hospital Kansas City·interventional·Posted Mar 8, 2007·Updated Jan 8, 2021

In Brief

A Phase 3 clinical trial evaluating Nutropin AQ for Prader-Willi Syndrome. Completed, enrolled 11 participants across 1 site.

Detailed Summary

The main research question this protocol aims to answer is whether treatment with growth hormone will impact body composition, quality of life, and energy balance in PWS adults, and if there is a loss of effects after cessation of treatment for at least 12 months.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrader-Willi Syndrome
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 8, 2007
Enrollment StartApr 1, 2005
Primary CompletionJan 1, 2012
TodayJul 2, 2026
Enrollment to primary: 6.8 yearsPosted 19.3 years ago

Interventions

Nutropin AQdrug

0.0125 mg/kg/day